Surely, there is enough debate here now to get this argument clarified. One thing is certain it is the only known drug in development that is likely to have dual action. HCV/HIV.
What we don't know is which big pharma BIT have been in discussions with and BIT225 fits with their interests. Without that knowledge writing off BIT as a loser is premature.
There are unique features that do set BIT225 apart. That is where any value lies. Impossible with imformation available to us, to value accurately.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.654M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $306 | 153.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 56 | 38556027 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 18612843 | 22 |
View Market Depth
| Last trade - 14.30pm 04/07/2025 (20 minute delay) ? |
| BIT (ASX) Chart |